Evidence map›Paper›PMID 41930344›Full record

ArticleMedComm2026

Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD-1 Inhibitor and Niraparib in GErm-Line-mutAted Metastatic Breast Cancer.

Jian Zhang, Yiqun Du, Yanchun Meng, Yizi Jin, Mingxi Lin, Xuchen Shao, Xiaojun Liu, Yuxin Mu, Yun Liu, Zhen Hu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jian ZhangPhase I Unit Fudan University Shanghai Cancer Center Shanghai China.
Yiqun DuPhase I Unit Fudan University Shanghai Cancer Center Shanghai China.
Yanchun MengPhase I Unit Fudan University Shanghai Cancer Center Shanghai China.
Yizi JinDepartment of Oncology Shanghai Medical College Fudan University Shanghai China.
Mingxi LinDepartment of Oncology Shanghai Medical College Fudan University Shanghai China.
Xuchen ShaoPhase I Unit Fudan University Shanghai Cancer Center Shanghai China.
Xiaojun LiuPhase I Unit Fudan University Shanghai Cancer Center Shanghai China.
Yuxin MuPhase I Unit Fudan University Shanghai Cancer Center Shanghai China.
Yun LiuState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China.
Zhen HuDepartment of Oncology Shanghai Medical College Fudan University Shanghai China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This phase II trial evaluated the efficacy and safety of combining niraparib with the PD-1 inhibitor HX008 in patients with metastatic breast cancer who had germline DNA damage response (DDR) mutations. The study included 37 patients, divided into a primary cohort of HER2-negative individuals with germline BRCA1/2 or PALB2 mutations (

Indexed as

BRCA mutationhomologous recombination deficiencymetastatic breast cancerniraparibprogrammed cell death protein 1 (PD‐1) inhibitor

Identifiers

PMID41930344
PMCPMC13042650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.